These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 31352982)
1. Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma. Chan A; Dogan A Surg Pathol Clin; 2019 Sep; 12(3):699-707. PubMed ID: 31352982 [No Abstract] [Full Text] [Related]
2. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes. Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S J BUON; 2015; 20(3):820-8. PubMed ID: 26214636 [TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031 [TBL] [Abstract][Full Text] [Related]
4. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715 [TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G; J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305 [TBL] [Abstract][Full Text] [Related]
6. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200 [TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Jardin F; Jais JP; Molina TJ; Parmentier F; Picquenot JM; Ruminy P; Tilly H; Bastard C; Salles GA; Feugier P; Thieblemont C; Gisselbrecht C; de Reynies A; Coiffier B; Haioun C; Leroy K Blood; 2010 Aug; 116(7):1092-104. PubMed ID: 20435884 [TBL] [Abstract][Full Text] [Related]
8. pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. Stewart DA; Bahlis N; Mansoor A Leuk Lymphoma; 2009 Aug; 50(8):1276-82. PubMed ID: 19562614 [TBL] [Abstract][Full Text] [Related]
9. Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology. Winter JN Curr Hematol Malig Rep; 2007 Oct; 2(4):235-41. PubMed ID: 20425375 [TBL] [Abstract][Full Text] [Related]
10. High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy. Choi YW; Ahn MS; Choi JH; Lee HW; Kang SY; Jeong SH; Park JS; Han JH; Kim JH; Sheen SS Int J Hematol; 2016 Feb; 103(2):210-8. PubMed ID: 26586460 [TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232 [TBL] [Abstract][Full Text] [Related]
13. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E; Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385 [TBL] [Abstract][Full Text] [Related]
14. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers. Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292 [TBL] [Abstract][Full Text] [Related]
15. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ennishi D; Takeuchi K; Yokoyama M; Asai H; Mishima Y; Terui Y; Takahashi S; Komatsu H; Ikeda K; Yamaguchi M; Suzuki R; Tanimoto M; Hatake K Ann Oncol; 2008 Nov; 19(11):1921-6. PubMed ID: 18573805 [TBL] [Abstract][Full Text] [Related]
16. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442 [TBL] [Abstract][Full Text] [Related]
17. Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. Vitolo U; Botto B; Capello D; Vivenza D; Zagonel V; Gloghini A; Novero D; Parvis G; Calvi R; Ariatti C; Milan I; Bertini M; Boccomini C; Freilone R; Pregno P; Orsucci L; Palestro G; Saglio G; Carbone A; Gallo E; Gaidano G Leukemia; 2002 Feb; 16(2):268-75. PubMed ID: 11840294 [TBL] [Abstract][Full Text] [Related]
18. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716 [TBL] [Abstract][Full Text] [Related]
20. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma. Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]